Genentech, Inc.

Laboratory Corporation of America Holdings

Exelixis, Inc.

Other

Genetech, Inc.

Monogram Biosciences, Inc.

John William Winslow

Leonard G Presta

Roman Urfer

Jeff Sperinde

Ingrid W Caras

Xueguang Jin

Gerald J Wallweber

Michael R Bates

Weidong Huang

Mojgan Haddad

Jodi Weidler

Jonathan Cagampang Heller

Arnon Rosenthal

Helen Louise Francis-Lang

Gordon Parry

R Glenn Hammonds, Jr

Gundo Diedrich

Ali Mukherjee

Darren Platt

Bindu Priya Reddy

Stephen J Williams

Yuling Luo

Andrew Roy Buchman

Laurie Goodman

Jennifer W Cook

Candace Swimmer

Colombe Chappey

Casey Kopczynski

Jonathan Scott Margolis

Allen James Ebens, Jr

Lucile A Gillett

Christian Burks

Greg Weddell

Michael Bates

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients

In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.

Her2 diagnostic methods

The disclosure provides methods of making antibodies specific for p95.

Methods of producing antibodies specific for p95

The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95.

Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95

NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.

Treatment methods using NGF variants

Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.

Pantropic neurotrophic factors

Pantropic neurothrophic factors

NGF variants

The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.

AL-1 neurotrophic factor treatments

The present invention provides methods of enhancing cognitive function in mammals by administering intracerebrally a homo-multimeric immunoadhesin molecule that contains the extracellular domain of AL-1, also known as ephrin-A5.

Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin

Vascular Endothelial Growth Factor Receptor (dmVEGFR) nucleic acids and proteins that have been isolated from are described. The dmVEGFR nucleic acids and proteins can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in dmVEGPR expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds which are potential therapeutics that interact with dmVEGFR protein. They can also be used in methods for studying dmVEGFR activity and identifying other genes that modulate the function of, or interact with, the dmVEGFR gene.

Invertebrate vascular endothelial growth factor receptor

Tandem pore domain weak inward rectifying K (TWIK) channel nucleic acids and proteins that have been isolated from and Leptinotarsa are described. The TWIK channel nucleic acids and proteins can be used to genetically modify metazoan invertebrate organisms, such as insects, coelomates, and pseudocoelomates, or cultured cells, resulting in TWIK channel expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds which are potential pesticidal agents or therapeutics that interact with TWIK channel proteins. They can also be used in methods for studying TWIK channel activity and identifying other genes that modulate the function of, or interact with, the TWIK channel gene.

Nucleic acids and polypeptides of invertebrate TWIK channels and methods of use

Growing community of inventors

El Granada, CA, United States of America

John William Winslow